CYP19A1 and cancer: Overall, available preclinical and clinical data suggest HBI-8000 play significant roles in cancer therapy, either as monotherapy in ATL and PTCL or in combination with mainstay treatment, such as immune CPIs or aromatase inhibitors, in solid tumors.